scholarly journals Prevalence and Risk Factors of Infection with High Risk Human Papilloma Viruses among HIV-Positive Women with Clinical Manifestations of Tuberculosis in a Middle-Income Country

Biomedicines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 683
Author(s):  
Maria Isaguliants ◽  
Marina Nosik ◽  
Anastasia Karlsen ◽  
Natalia Petrakova ◽  
Marina Enaeva ◽  
...  
Keyword(s):  
Hpv Vaccine ◽  
Hpv Infection ◽  
Middle Income Country ◽  
Middle Income ◽  
Women Living With Hiv ◽  
Hpv Types ◽  
Study Participants ◽  
Living With Hiv ◽  
Hpv16 E5 ◽  
Hiv 1

Women living with HIV-1 are at high risk of infection with human papillomavirus of high carcinogenic risk (HR HPVs). M. tuberculosis (TB) promotes HPV infection and increases the risk to develop HPV-associated cancer. Our knowledge of persisting HR HPVs genotypes, and of the factors promoting HR HPV infection in people living with HIV-1 with clinical TB manifestations is sparse. Here, we analyzed 58 women living with HIV-1 with clinical TB manifestations (WLWH with TB) followed up in specialized centers in Russia, a middle income country endemic for HIV-1 and TB, for the presence in cervical smears of DNA of twelve HR HPV genotypes. DNA encoding HPV16 E5, E6/E7 was sequenced. Sociodemographic data of patients was collected by questionnaire. All women were at C2-C3 stages of HIV-infection (by CDC). The majority were over 30 years old, had secondary education, were unemployed, had sexual partners, experienced 2–3 pregnancies and at least one abortion, and were smokers. The most prevalent was HPV16 detected in the cervical smears of 38% of study participants. Altogether 34.5% of study participants were positive for HR HPV types other than HPV16; however, but none of these types was seen in more than 7% of tested samples. Altogether, 20.7% of study participants were positive for several HR HPV types. Infections with HPVs other than HPV16 were common among WLWH with generalized TB receiving combined ART/TB-therapy, and associated with their ability to work, indirectly reflecting both their health and lifestyle. The overall prevalence of HR HPVs was associated with sexual activity of women reflected by the number of pregnancies, and of HPV 16, with young age; none was associated to CD4+-counts, route of HIV-infection, duration of life with HIV, forms of TB-infection, or duration of ART, characterizing the immune status. Thus, WLWH with TB—especially young—were predisposed to infection with HPV16, advancing it as a basis for a therapeutic HPV vaccine. Phylogenetic analysis of HPV16 E5, E6/E7 DNA revealed no common ancestry; sequences were similar to those of the European and American HPV16 strains, indicating that HPV vaccine for WLWH could be the same as HPV16 vaccines developed for the general population. Sociodemographic and health correlates of HR HPV prevalence in WLWH deserve further analysis to develop criteria/recommendations for prophylactic catch-up and therapeutic HPV vaccination of this highly susceptible and vulnerable population group.

scholarly journals 926. Antibody Response to HPV Vaccination in Pediatric and Adolescent People Living with HIV (PLWH)

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S496-S497
Author(s):  
Roukaya Al Hammoud ◽  
Elizabeth R Unger ◽  
Gitika Panicker ◽  
Gabriela P Del Bianco ◽  
Gloria Heresi ◽  
...  
Keyword(s):  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Pediatric Hiv ◽  
People Living With Hiv ◽  
Hiv Viral Load ◽  
Exact Test ◽  
Peak Titer ◽  
Hpv Types ◽  
Living With Hiv

Abstract Background Immune dysfunction related to HIV infection is associated with an inability to clear HPV infection and may compromise the immunogenicity of quadrivalent HPV vaccine Gardasil® (4v HPV). Methods Between 2005 and 2017, males and females 7 to 20 years old age, were offered 3-dose 4v HPV vaccine. Plasma IgG titers to HPV 6 (H6), 11 (H11), 16 (H16) and 18 (H18) were measured using multiplex VLP-based ELISA. For the 36 patients, median interval from 1st dose to 2nd and 3rd doses were 73 and 216 days. Plasma sample 1 was collected at median of 91 days after dose 1, sample 2, 169 and sample 3, 740 after respective vaccine doses. A 4th sample was available for 26 patients, median 2327 days after dose 1. Rank-sum test, Χ 2 or Fisher’s Exact Test were employed. Results Before vaccination, 10 (28%) were seropositive to 1 or more HPV types. The baseline seropositives were older than seronegatives (16 years vs 11; p=0.007). After dose 3 all participants had an Ab response to at least 1 HPV type and 32 (89%) were seropositive for 4 HPV types. Seroconversions were H18, 87%; H16 97%; H11, 100%; H6, 97%. Seroconversions after 1 dose of 4v HPV among the baseline seronegatives were 61%, 90%, 86% and 86%, respectively and 22 became seropositive for all 4 types. The 4 baseline seronegative PLWH with partial seroconversion had higher median HIV viral load (VL) compared to baseline seronegative group with full seroconversion (12,920 vs 101 copies/ml; p = 0.052), but had comparable CD4 counts. The rate of post vaccination seropositivity and baseline to peak titer response for each HPV type was not significantly different for baseline sero-groups. Among baseline seronegative, all 19 sampled distant from vaccination remained seropositive to at least 1 HPV type (84% to 3 or more types) and 6 (32%) became seronegative (sero-reversion). Those showing sero-reversion had higher VL compared to the 14 who remained seropositive (9100 vs 48; p =0.015). Time from last dose of 4v HPV to sample 4, CD4%, age, gender, and race/ethnicity were similar between the groups. Bar Graphs representing Ab response to the 4 HPV types following each dose of 4v HPV vaccine Conclusion In the complex environment of a pediatric HIV specialty clinic, most PLWH mounted Ab responses to 4v HPV that were durable. H18 was least immunogenic. Patients with higher HIV VL were less likely to seroconvert for all types and were more likely to sero-revert. Disclosures All Authors: No reported disclosures

scholarly journals Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1

2018 ◽  
Vol 6 ◽  
pp. 15-21 ◽  
Author(s):  
Michelle S. Cespedes ◽  
Minhee Kang ◽  
Erna Milunka Kojic ◽  
Triin Umbleja ◽  
Catherine Godfrey ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Sustained Response ◽  
Women Living With Hiv ◽  
Quadrivalent Hpv Vaccine ◽  
Living With Hiv ◽  
Hiv 1

Fatores associados à infecção pelo HPV entre mulheres vivendo com HIV / Factors associated with HPV infection among women living with HIV

2021 ◽  
Vol 4 (4) ◽  
pp. 17802-17819
Author(s):  
Kamilla Azevedo Bringel ◽  
Karina Maria Azevedo Bringel ◽  
Cláudia Renata dos Santos Barros
Keyword(s):  
Hpv Infection ◽  
Factors Associated ◽  
Women Living With Hiv ◽  
Living With Hiv

scholarly journals Epidemiologic and clinical characteristics of pregnant women living with HIV/AIDS in a region of Southern Brazil where the subtype C of HIV-1 infection predominates

2011 ◽  
Vol 15 (4) ◽  
pp. 349-355 ◽  
Author(s):  
Sandra Aparecida Manenti ◽  
João Galato Júnior ◽  
Elizângela da Silva Silveira ◽  
Roberto Teixeira Oenning ◽  
Priscyla Waleska Targino de Azevedo Simões ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Clinical Characteristics ◽  
Southern Brazil ◽  
Subtype C ◽  
Women Living With Hiv ◽  
Living With Hiv ◽  
Hiv 1 ◽  
Hiv Aids

7. High prevalence of human papillomavirus (HPV) infection and high-grade anal intraepithelial neoplasia in HIV-seropositive women, the EVVA study

Sexual Health ◽  
2013 ◽  
Vol 10 (6) ◽  
pp. 573
Author(s):  
Francois Coutlée ◽  
Sophie Rodrigues-Coutlée ◽  
Marie Munoz ◽  
Marie Helene Mayrand ◽  
Louise Charest ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Intraepithelial Neoplasia ◽  
Hpv Infection ◽  
Anal Intraepithelial Neoplasia ◽  
High Grade ◽  
Women Living With Hiv ◽  
Increased Risk ◽  
High Prevalence ◽  
Living With Hiv ◽  
Hiv Seropositive

Background Women living with HIV are at increased risk of anal HPV infection, anal intraepithelial neoplasia (AIN) and anal cancer. This study will describe the burden of infection and of high-grade AIN (AIN-2,3) in a population of HIV-infected women living in Montreal, Canada. Methods: HIV-seropositive women aged ≥18 years old are recruited in the cohort study EVVA. Participants are followed every 6 months for 2 years with questionnaires, cervical/anal HPV testing, cervical/anal cytology and high-resolution anoscopy (HRA). Results: Of the 116 first participants, 88 (75.9%, 95% confidence interval (CI) 67.3–82.8) were infected by HPV in the anal canal. In contrast, 58 of these participants (50%, 95% CI 41.1–59.0) had cervical HPV infection). The most frequent types were HPV16 (n = 19), HPV51 (n = 18), HPV81 and HPV62 (n = 15 each), and HPV45 and HPV58 (n = 14 for each). An average of 2.3 ± 3.1 HPV types (median of 1) were detected per anal sample. Of the 89 participants with satisfactory cytology, 5 had high-grade squamous intraepithelial lesions. HRA from 95 women revealed 17 AIN2,3 (17.9%, 95% confidence interval (CI) 11.4–26.9), 43 AIN1 (45.3%, 95% CI 35.6–55.3), and only 35 without AIN (36.8%, 95% CI 27.8–46.9). Biopsies from 4 women gave undetermined results. Conclusions: Our study revealed that anal HPV infection was more frequently detected than cervical infection in HIV-seropositive women. Prevalent AIN2,3 is a significant problem in women infected with HIV. Prospective follow-up of women with AIN1 will disclose the proportion of women with progressive AIN.

scholarly journals Epidemiologic and clinical characteristics of pregnant women living with HIV/AIDS in a region of Southern Brazil where the subtype C of HIV-1 infection predominates

2011 ◽  
Vol 15 (4) ◽  
pp. 349-355 ◽  
Author(s):  
Sandra Aparecida Manenti ◽  
João Galato Júnior ◽  
Elizângela da Silva Silveira ◽  
Roberto Teixeira Oenning ◽  
Priscyla Waleska Targino de Azevedo Simões ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Clinical Characteristics ◽  
Southern Brazil ◽  
Subtype C ◽  
Women Living With Hiv ◽  
Living With Hiv ◽  
Hiv 1 ◽  
Hiv Aids
Sign in / Sign up

Export Citation Format

Share Document